Elevated level of peripheral CD8+CD28− T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy
- 21 April 2013
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 62 (6) , 1123-1130
Abstract
Purpose Suppression of cellular immunity resulting from tumorigenesis and/or therapy might promote cancer cells’ growth, progression and invasion. Here, we explored whether T lymphocyte subtypes from peripheral blood of metastatic breast cancer (MBC) female patients could be used as alternative surrogate markers for cancer progress. Additionally, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IFN-γ, and transforming growth factor-β1 were quantitated from MBC and healthy volunteers. Experimental design This study included 89 female MBC patients during the post-salvage chemotherapy follow-up and 50 age- and sex-matched healthy volunteers as control. The percentages of T lymphocyte subpopulations from peripheral blood and plasma levels of cytokines were measured. Results Both CD8+CD28− and CD4+CD25+ were elevated in MBC patients compared to the control cohort (P < 0.05). In contrast, CD3+ and CD8+CD28+cells were significantly lower in MBC patients (P < 0.0001, P = 0.045, respectively). MBC patients had elevated levels of immunosuppressive cytokines IL-6 and IL-10. Patients with elevated CD8+CD28− and CD4+CD25+ cells showed increased levels of IL-6, and only patients with elevated CD8+CD28− had decreased interferon-γ. Univariate analysis indicated increased CD3+CD4+ or CD8+CD28+correlated with prolonged progression-free survival (PFS), while elevated CD8+CD28−associated with shorten PFS. The percent of CD8+CD28− T lymphocytes is an independent predictor for PFS through multivariate analysis. Conclusions This study suggests that progressive elevated levels of CD8+CD28− suppressor T lymphocytes represent a novel independent predictor of PFS during post-chemotherapy follow-up.Keywords
This publication has 36 references indexed in Scilit:
- Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor β2 (IL-12Rβ2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of RecurrenceJournal of Clinical Oncology, 2013
- Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesClinical and Experimental Immunology, 2012
- Immune microenvironments in solid tumors: new targets for therapyGenes & Development, 2011
- CD8+ CD28− and CD8+ CD57+ T cells and their role in health and diseaseImmunology, 2011
- Regulatory T cells and breast cancer: implications for immunopathogenesisCancer and Metastasis Reviews, 2010
- Immune Suppression in Head and Neck Cancers: A ReviewJournal of Immunology Research, 2010
- Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunityImmunology, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Foxp3 Expressing CD4+ CD25+ and CD8+CD28− T Regulatory Cells in the Peripheral Blood of Patients with Lung Cancer and Pleural MesotheliomaHuman Immunology, 2006
- Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28− T cells and inhibit both T-Cell proliferation and CTL functionHuman Immunology, 2004